Full Press Release Details
and New York, NY, 24 March, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"),
an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ("DED") to address
the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited,
an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 of the Company's ADSs on NASDAQ
at a price of US$1.40 per ADS (which would be equivalent to the purchase of 650,000 ordinary shares of no par value ("Ordinary Shares")
at a price of 0.0175 each).
| 1. | Details of PDMR / person closely associated | ||
| a) | Name | Gabriele Cerrone | |
| 2. | Reason for the notification | ||
| a) | Position / status | Chairman | |
| b) | Initial notification /amendment | Initial notification | |
| 3. | Details of the issuer | ||
| a) | Name | OKYO Pharma Limited | |
| b) | LEI | 213800VVN5CB56Y15A05 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument | ADSs representing 65 Ordinary Shares of no par value | |
| b) | Identification code of the Financial Instrument | ISIN for OKYO Pharma Limited GG00BD3FV870 | |
| c) | Nature of the transaction | Market Purchase | |
| d) | Price(s) and volume(s) | $1.40 - 10,000 | |
| f) | Date of the transaction | 23 March 2023 | |
| g) | Place of the transaction | NASDAQ |
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
| Broker | Robert Emmet, Optiva Securities Limited | +44 (0)20 3981 4173 |
Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the
Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange
plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For
further information, please visit www.okyopharma.com.
is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells
of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce
a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing
activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of
the lipid anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.